Neuropharmacology (2019) 157:107668
While recent studies have been promising, the drugs haven't been approved by the Food and Drug Administration (FDA) for this purpose yet
Modulates Blood Lipids : GLP-1 can lead to favorable changes in blood lipid profiles, potentially lowering LDL ("bad") cholesterol and triglycerides while increasing HDL ("good") cholesterol
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomized, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Uma abordagem essencial para o tratamento do DM2 envolve conscientizar o indivduo sobre sua condio, ajudando-o a compreender o que o diabetes, suas causas e como ele pode contribuir para o agravamento de outras patologias
In a number of studies, GLP-1R agonists such as liraglutide, exenatide and lixisenatide can reduce neuroinflammation in AD models, thereby improving cognitive dysfunction (140, 141, 144148)